Rogers Turnaround: Can Cost Cuts Finally Beat the Losses?

Forward-Looking Analysis

Rogers' 2026Q1 earnings are expected to reflect ongoing progress in its turnaround strategy, driven by structural cost cuts and operational improvements in core markets. Analysts and company updates suggest stronger efficiency and early traction in industrial, ADAS, and renewable energy. Earnings estimates are not explicitly stated, but the forward P/E of ~45x and positive 30-day return of 19.8% indicate investor optimism. The company is still reporting a net loss on $810.8M revenue, but analysts are watching for signs that cost discipline and market exposure are yielding durable results.

Historical Performance Review

In 2025Q4, Rogers reported revenue of $201.50 million, a net income of $4.60 million, and an EPS of $0.26. The company's gross profit stood at $63.50 million, reflecting early signs of improved profitability amid ongoing cost restructuring efforts.

Additional News

No additional earnings-related news for Rogers was identified in the provided data. Recent content focused on unrelated companies, including Zions Bancorporation, Recursion Pharmaceuticals, and Pulnovo Medical.

Summary & Outlook

Rogers is showing early signs of financial stabilization with cost reductions and efficiency gains. While still unprofitable, its forward P/E and positive share price momentum indicate market confidence in its turnaround. The company's exposure to industrial and renewable energy markets offers growth potential, though valuation risks and insider selling remain a concern. The 2026Q1 report will be a key test of whether operational improvements are translating to sustainable profitability. Investors should watch for concrete progress on cost savings and order trends in key sectors.